reports
- Vikash Harlalka
Autumn for Broadband 2Q25
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Net adds remained nearly flat compared to a year ago (when adjusted for ACP impact) but were within the pre-pandemic norm. Industry subscriber trends have mostly stabilized over the past 3 quarters, but y/y growth remains below pre-pandemic levels.
- Vikash Harlalka
Comcast Post-2Q25 Model Update
In this note, we cover changes to our estimates, and comparisons with guidance and consensus. Please see separate notes reviewing results (here) and thoughts following the earnings call. The most significant changes are slightly lower broadband losses and higher FCF in 2025. No change to thesis. Price target is $37 (+12%).
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
- Alicia Reese
- Kade Barr
- Matthew McCartney
- Vikash Harlalka
CMCSA: Thoughts following the 2Q25 call
In this note we provide our thoughts on connectivity revenue and EBITDA, the changes in pricing strategy, broadband ARPU growth and wireless net adds in back half of the year, fiber overbuilds, savings from tax reforms and usage of the proceeds. Finally, we touch on what to do with the stock.
- Vikash Harlalka
- Wedbush Research
- Alicia Reese
- Kade Barr
- Matthew McCartney
- Jonathan Chaplin
AT&T Model Update
We have updated the model following results. Changes to the segments are not material, but changes to capex, cash taxes and free cash flow in light of the OBBBA are. For thoughts following the call, click here. For a review of results, click here. (Rating: Buy; TP: $32; Total Return: +20%).
- Jonathan Chaplin
AT&T quick thoughts following the call 2Q25
In this note we cover evolving thoughts on the implications of the new Cable MVNO, the implications of AT&T’s revised capital allocation decisions, new insights on the pace of fiber deployment, a shift in the FWA strategy, the implications of both for cable, comments on spectrum purchases, the implications for EchoStar, and an early take on mobile and broadband market growth.
- Jonathan Chaplin
AT&T 2Q25 Quick Take: Results strong; FCF guide increased, but less th...
Postpaid phone adds beat estimates, which will come as a relief following Verizon’s results. Service revenue, EBITDA, EPS, and FCF were all slightly better than expected. The Company increased FCF guidance following OBBBA, but by less than some had hoped. In addition, the Company did not commit to increasing share repurchases with the increased FCF.
Roku Inc: 1 director
A director at Roku Inc sold/sold after exercising options 212,559 shares at 95.000USD and the significance rating of the trade was 93/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
- Jonathan Chaplin
New Cable MVNO – implications for Cable and Mobile operators
Charter and Comcast announced that they have signed an MVNO with T-Mobile that will target new business customers (here). In this quick note we provide thoughts on implications for Verizon, T-Mobile, Charter, Comcast, and the industry more broadly.
- Dan Salmon
- Blair Levin
Media Consolidation: Will FOX (Like CMSCA and DIS) Be in a Trump Trans...
As the Skydance/Paramount deal has demonstrated, the Trump FCC will address media transactions through a political lens. In this note, we discuss the implications for the sector of FOX potentially finding itself in the same position as CSMCA and DIS when it comes to the upcoming media consolidation, as well as other implications of the Colbert Affair and the federal defunding of PBS.
Moody's Ratings assigns Prime-2 short term rating to Netflix's commerc...
Moody's Ratings (Moody's) assigned a Prime-2 short term rating to the new commercial paper program of Netflix, Inc. (Netflix). Netflix's existing A3 senior unsecured notes ratings and the positive rating outlook remain unchanged. The Prime-2 rating reflects our expectation that Netflix will mainta...
- Wedbush Research
VRNS VARONIS SYSTEMS INC.
TSLA TESLA INC
QLYS QUALYS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
MCS MARCUS CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
FB FACEBOOK INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CNK CINEMARK HOLDINGS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
AMZN AMAZON.COM INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
S SENTINELONE INC
RBRK RUBRIK INC
- Alicia Reese
- Kade Barr
- Matthew McCartney
- Scott Devitt
- Dan Salmon
Netflix (NFLX, Neutral, $975 target) NFLX First Take: Ads on track, bu...
In our first take on tonight’s results, we dig into: 1. Steady beat and raise driven by FX, good fundamentals and late 2Q surge 2. Ad revenue still expected to double this year, multiple levers improving 3. 1H25 engagement report shows viewing per member slightly down 4. TF1 deal adds new vector for content strategy, no details on terms, including ads
- Dan Salmon
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.